NCT00242372终止3 期
A 24-Week Randomised, Double-Blind, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Added to the Therapy of Patients With Type 2 Diabetes Poorly Controlled on Insulin
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- AstraZeneca
- 入组人数
- 370
- 试验地点
- 71
- 主要终点
- Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c)
研究概览
简要总结
This is a 24-week randomized, double-blind, multi-center, placebo-controlled study of tesaglitazar in patients with type 2 diabetes who are not adequately controlled on insulin (along or in combination with one or more oral antidiabetic agents in addition to diet and lifestyle advice). The study comprises a 3-week enrollment period and a 24-week randomized, double blind, multi-center, placebo-controlled treatment period and a 3-week follow-up. Patients must receive at least 30 units of insulin per day and will continue their current oral antidiabetic treatment regimen throughout the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provision of a written informed consent
- •Men or women who are >=18 years of age
- •Female patients: postmenopausal, hysterectomized, or if of childbearing potential, using a reliable method of birth control
- •Diagnosed with type 2 diabetes for less than 20 years and receiving at least 30 U insulin per day
排除标准
- •Type 1 diabetes
- •New York Heart Association heart failure Class III or IV
- •Treatment with any thiazolidinedione class of antidiabetic agents
- •History of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like Actos or Avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin)
- •History of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells)
- •Creatinine levels above twice the normal range
- •Creatine kinase above 3 times the upper limit of normal
- •Received any investigational product in other clinical studies within 12 weeks
- •Any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study
结局指标
主要结局
Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c)
次要结局
- Changes in the following variables from baseline to the end of the randomized treatment period:
- The change in fasting plasma glucose (FPG), insulin, proinsulin and C-peptide from baseline to the end of the randomized treatment period
- Pharmacokinetics of tesaglitazar
- Insulin sensitivity by assessment of change in the calculated variable homeostasis assessment model from baseline to the end of the randomized treatment period
- Lipid parameters (triglyceride [TG], total cholesterol, high-density lipoprotein cholesterol [HDL C], non-HDL C, low-density lipoprotein cholesterol [LDL C], apolipoproteins [Apo] A-I, Apo B, Apo CIII, free fatty acids, lipoprotein particle size and c
- C-reactive protein, LDL C/HDL C ratio and Apo B/Apo A-I ratio
- FPG, homeostasis assessment model, insulin, proinsulin, C-peptide
- Tumor necrosis factor-alpha, intracellular adhesion molecule-1
- Fibrinogen
- Urinary albumin excretion
- Waist/hip ratio
- Responder analyses for HbA1c, FPG, TG, HDL C, total cholesterol, non HDL C and LDL C according to pre-specified values
- Proportion of patients reaching pre-specified target levels for HbA1c, FPG, TG, HDL C, non-HDL C and LDL C
- Safety and tolerability of tesaglitazar by assessment of adverse events, laboratory values, electrocardiogram, pulse, blood pressure, hypoglycemic events, body weight, cardiac evaluation, and physical examination
- To validate the Work Productivity and Activity Impairment-Diabetes Questionnaire (WPAI-Diabetes) and the Diabetes Productivity Impairment Questionnaire (DPIQ) in patients with type 2 diabetes and to explore the effects of tesaglitazar (0.5 mg) on pati
研究者
研究点 (71)
Loading locations...
相似试验
已完成
4 期
Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart FailureType 2 Diabetes MellitusHeart FailureNCT02917031AstraZeneca348
终止
3 期
GALLANT 6 Tesaglitazar vs. PioglitazoneDiabetes Mellitus, Type 2NCT00214565AstraZeneca1,450
终止
3 期
GALLANT 7 Tesaglitazar Add-on to SulphonylureaType 2 DiabetesNCT00251940AstraZeneca555
终止
3 期
GALLANT 8 Tesaglitazar Add-on to MetforminType 2 DiabetesNCT00251953AstraZeneca555
终止
3 期
GALLANT 2 Tesaglitazar vs. PlaceboType 2 DiabetesNCT00252772AstraZeneca80